Corticosteroids for COVID-19 : the search for an optimum duration of therapy
| Errataetall: |
CommentOn: Lancet Respir Med. 2020 Dec;8(12):1170-1172. - PMID 33129421 |
|---|---|
| Media Type: |
Electronic Article |
| Year of Publication: |
2021 |
|---|
| Contained In: |
The Lancet. Respiratory medicine - Vol. 9, No. 1 (2021), p. e8 |
|---|
| Language: |
English |
|---|
| Contributors: |
|---|
| Urls: |
|---|
| Keywords: |
*COVID-19 |
|---|
| Notes: |
Date Completed 12.01.2021 Date Revised 12.01.2021 published: Print-Electronic CommentOn: Lancet Respir Med. 2020 Dec;8(12):1170-1172. - PMID 33129421 Citation Status MEDLINE Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine |
|---|
| Physical Description: |
Online-Ressource |
|---|
| doi: |
10.1016/S2213-2600(20)30530-0 |
|---|---|
| PMID: |
33248469 |
| PPN (Catalogue-ID): |
NLM319146669 |
|---|
| LEADER | 01854nma a2200553 c 4500 | ||
|---|---|---|---|
| 001 | NLM319146669 | ||
| 003 | DE-601 | ||
| 005 | 20210113215122.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201130s2021 000 0 eng d | ||
| 024 | 7 | |a 10.1016/S2213-2600(20)30530-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed21n1109.xml |
| 035 | |a S2213-2600(20)30530-0 | ||
| 035 | |a (DE-599)NLM33248469 | ||
| 040 | |b ger |c GBVCP | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Mishra, Gyanshankar P | |
| 245 | 1 | 0 | |a Corticosteroids for COVID-19 |h Elektronische Ressource |b the search for an optimum duration of therapy |
| 300 | |a Online-Ressource | ||
| 500 | |a Date Completed 12.01.2021 | ||
| 500 | |a Date Revised 12.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Lancet Respir Med. 2020 Dec;8(12):1170-1172. - PMID 33129421 | ||
| 500 | |a Citation Status MEDLINE | ||
| 500 | |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine | ||
| 611 | 2 | 7 | |a Letter |2 gnd |
| 611 | 2 | 7 | |a Comment |2 gnd |
| 653 | 2 | |a Adrenal Cortex Hormones |6 D000305 | |
| 653 | 2 | |a *COVID-19 |6 D000086382 | |
| 653 | 2 | |a Dexamethasone |6 D003907 | |
| 653 | 2 | |a Duration of Therapy |6 D000081206 | |
| 653 | 2 | |a Humans |6 D006801 | |
| 653 | 2 | |a SARS-CoV-2 |6 D000086402 | |
| 655 | 7 | |a Adrenal Cortex Hormones |2 gnd | |
| 655 | 7 | |a Dexamethasone |2 gnd | |
| 655 | 7 | |a 7S5I7G3JQL |2 gnd | |
| 689 | 0 | 0 | |A f |a Letter |
| 689 | 0 | 1 | |A f |a Comment |
| 689 | 0 | |5 DE-601 | |
| 689 | 2 | 0 | |a Adrenal Cortex Hormones |
| 689 | 2 | 1 | |a Dexamethasone |
| 689 | 2 | 2 | |A r |a 7S5I7G3JQL |
| 689 | 2 | |5 DE-601 | |
| 700 | 1 | |a Mulani, Jasmin | |
| 773 | 0 | 8 | |i in |t The Lancet. Respiratory medicine |g Vol. 9, No. 1 (2021), p. e8 |q 9:1<e8 |w (DE-601)NLM231937121 |x 2213-2619 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/S2213-2600(20)30530-0 |3 Volltext |
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 1 |b 16 |c 01 |h e8 | ||